Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 14, 2007

Indivumed to Provide Roche Diagnostics with Immunohistochemistry Services and Clinical Specimens

  • Indivumed will analyze various biomarkers and drug targets in the area of oncology for Roche Diagnostics. This should enable Roche to efficiently develop novel targeted therapies for cancer, the companies note.

    Indivumed will apply its automated immunohistochemistry (IHC) service platform. It will also provide a selection of tumor tissue sections from its tumor biobank as well as specifically collected clinical samples.

    Indivumed currently has a tumor biobank of over 6,500 patient cases, the company reports. It is a resource for the firm’s internal cancer research in biomarkers and primary cell drug screening as well as for for pharmaceutical and biopharma partners through tumor biobank access and IHC services.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »